Newcastle Disease Viruses and Uses Thereof

a technology of newcastle disease and viruses, applied in the field of newcastle disease viruses, can solve the problems of only marginal success of naturally occurring strains of ndv in these clinical trials for advanced human cancers, and achieve the effects of reducing or ameliorating the severity of cancer, preventing the recurrence of a symptom, and reducing the duration of a symptom

Inactive Publication Date: 2014-09-18
MT SINAI SCHOOL OF MEDICINE +1
View PDF2 Cites 136 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0049]As used herein, the terms “treat” and “treating” in the context of the administration of a therapy refers to a treatment/therapy from which a subject receives a beneficial effect, such as the reduction, decrease, attenuation, diminishment, stabilization, remission, suppression, inhibition or arrest of the development or progression of cancer, or a symptom thereof. In certain embodiments, the treatment/therapy that a subject receives results in at least one or more of the following effects: (i) the reduction or amelioration of the severity of cancer and/or a symptom associated therewith; (ii) the reduction in the duration of a symptom associated with cancer; (iii) the prevention in the recurrence of a symptom associated with cancer; (iv) the regression of cancer and/or a symptom associated therewith; (v) the reduction in hospitalization of a subject; (vi) the reduction in hospitalization length; (vii) the increase in the survival of a subject; (viii) the inhibition of the progression of cancer and/or a symptom associated therewith; (ix) the enhancement or improvement the therapeutic effect of another therapy; (x) a reduction or elimination in the cancer cell population; (xi) a reduction in the growth of a tumor or neoplasm; (xii) a decrease in tumor size; (xiii) a reduction in the formation

Problems solved by technology

However, the success of naturally-occurring strains of NDV in these cli

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Newcastle Disease Viruses and Uses Thereof
  • Newcastle Disease Viruses and Uses Thereof
  • Newcastle Disease Viruses and Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0071]In one aspect, presented herein are chimeric Newcastle disease viruses (NDVs) engineered to express an agonist of a co-stimulatory signal of an immune cell and / or an antagonist of an inhibitory signal of an immune cell. In a specific embodiment, presented herein are chimeric NDVs, comprising a packaged genome which encodes an agonist of a co-stimulatory signal of an immune cell, wherein the agonist is expressed. In a specific embodiment, presented herein are chimeric NDVs, comprising a packaged genome which encodes an antagonist of an inhibitory signal of an immune cell, wherein the antagonist is expressed.

[0072]In another aspect, presented herein are methods for propagating the NDVs described herein (e.g., chimeric NDVs described herein). The NDVs described herein (e.g., chimeric NDVs described herein) can be propagated in any cell, subject, tissue, organ or animal susceptible to a NDV infection.

[0073]In another aspect, presented herein are compositions comprising an NDV desc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Inhibitionaaaaaaaaaa
Login to view more

Abstract

Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.

Description

[0001]This application claims priority to U.S. Provisional Application No. 61 / 782,994, filed on Mar. 14, 2013, which is incorporated by reference herein in its entirety.[0002]This invention was made, in part, with Government support under award numbers 5T32CA009207-35 and HHSN26620070010C from the National Institutes of Health. The Government has certain rights in this invention.1. INTRODUCTION[0003]Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/76A61K39/395
CPCA61K39/3955A61K35/768C07K16/2818C07K16/2827A61K2039/505C12N2760/18122C12N2760/18132C12N2760/18143A61P35/00C07K16/2878C07K2317/76C12N7/00C12N2760/18121C12N2760/18133
Inventor PALESE, PETERGARCIA-SASTRE, ADOLFOZAMARIN, DMITRIYALLISON, JAMESWOLCHOK, JEDD D.
Owner MT SINAI SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products